Belite Bio files marketing‑authorization applications for tinlarebant in Singapore, UK and Switzerland
Belite Bio announced that it has lodged Marketing Authorization Applications for its oral therapy tinlarebant with the health authorities of Singapore, the United Kingdom and Switzerland. The filings were made through the Access Consortium, a joint review mechanism among the three regulators. The company also maintains pending submissions in the United States and Japan, with the U.S. review slated to conclude on 12 February 2027.
Why it matters
If the applications succeed, tinlarebant would become the first approved treatment for Stargardt disease type 1 in those three markets, potentially unlocking new revenue streams for Belite Bio. The U.S. decision date gives investors a clear timeline for a major regulatory milestone.
Key facts
- 1Belite Bio submitted Marketing Authorization Applications for tinlarebant to Singapore, the United Kingdom and Switzerland. stocktitan.net
- 2The three filings were processed via the Access Consortium framework involving the Health Sciences Authority, the Medicines and Healthcare products Regulatory Agency and Swissmedic. stocktitan.net
- 3The U.S. new‑drug application for tinlarebant has a Prescription Drug User Fee Act target action date of 12 February 2027. tradingview.com
- 4Tinlarebant met the primary endpoint in a Phase 3 trial (DRAGON) in adolescent and adult patients with Stargardt disease type 1. investing.com
- 5Belite Bio reported $276.4 million in cash and cash equivalents for the quarter ended 31 March 2026. rttnews.com
- 6The company’s shares have traded between $79.05 and $200.00 over the prior 52 weeks. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.